1
|
Su M, Fleischer T, Grosheva I, Horev MB, Olszewska M, Mattioli CC, Barr H, Plotnikov A, Carvalho S, Moskovich Y, Minden MD, Chapal-Ilani N, Wainstein A, Papapetrou EP, Dezorella N, Cheng T, Kaushansky N, Geiger B, Shlush LI. Targeting SRSF2 mutations in leukemia with RKI-1447: A strategy to impair cellular division and nuclear structure. iScience 2024; 27:109443. [PMID: 38558935 PMCID: PMC10981050 DOI: 10.1016/j.isci.2024.109443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 02/07/2024] [Accepted: 03/05/2024] [Indexed: 04/04/2024] Open
Abstract
Spliceosome machinery mutations are common early mutations in myeloid malignancies; however, effective targeted therapies against them are still lacking. In the current study, we used an in vitro high-throughput drug screen among four different isogenic cell lines and identified RKI-1447, a Rho-associated protein kinase inhibitor, as selective cytotoxic effector of SRSF2 mutant cells. RKI-1447 targeted SRSF2 mutated primary human samples in xenografts models. RKI-1447 induced mitotic catastrophe and induced major reorganization of the microtubule system and severe nuclear deformation. Transmission electron microscopy and 3D light microscopy revealed that SRSF2 mutations induce deep nuclear indentation and segmentation that are apparently driven by microtubule-rich cytoplasmic intrusions, which are exacerbated by RKI-1447. The severe nuclear deformation in RKI-1447-treated SRSF2 mutant cells prevents cells from completing mitosis. These findings shed new light on the interplay between microtubules and the nucleus and offers new ways for targeting pre-leukemic SRSF2 mutant cells.
Collapse
Affiliation(s)
- Minhua Su
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
- Department of Molecular and Cellular Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Tom Fleischer
- Department of Molecular and Cellular Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Inna Grosheva
- Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Melanie Bokstad Horev
- Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Malgorzata Olszewska
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Camilla Ciolli Mattioli
- Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Haim Barr
- Wohl Institute for Drug Discovery, Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel
| | - Alexander Plotnikov
- Wohl Institute for Drug Discovery, Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel
| | - Silvia Carvalho
- Wohl Institute for Drug Discovery, Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel
| | - Yoni Moskovich
- Department of Molecular and Cellular Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Mark D. Minden
- Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, ON Canada
| | - Noa Chapal-Ilani
- Department of Molecular and Cellular Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Alexander Wainstein
- Department of Molecular and Cellular Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Eirini P. Papapetrou
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Nili Dezorella
- Electron Microscopy Unit, Weizmann Institute of Science, Rehovot, Israel
| | - Tao Cheng
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
| | - Nathali Kaushansky
- Department of Molecular and Cellular Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Benjamin Geiger
- Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel
| | - Liran I. Shlush
- Department of Molecular and Cellular Biology, Weizmann Institute of Science, Rehovot, Israel
- Molecular Hematology Clinic, Maccabi Healthcare, Tel Aviv, Israel
- Division of Hematology, Rambam Healthcare Campus, Haifa, Israel
| |
Collapse
|
2
|
Barnes M, Shklar V, Patel D, Staszewski H. Young Woman with Unexplained Neutropenia and Neutrophils with Bilobed Nuclei: Marrow Findings. Case Rep Hematol 2023; 2023:8844577. [PMID: 37790742 PMCID: PMC10545456 DOI: 10.1155/2023/8844577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2023] [Revised: 08/27/2023] [Accepted: 09/07/2023] [Indexed: 10/05/2023] Open
Abstract
A 27-year-old female with a history of chronic sinusitis was referred for the evaluation of asymptomatic neutropenia. The differential demonstrated a mild neutropenia, which eventually resolved on subsequent evaluation. The liver and the spleen were not palpable. Peripheral flow cytometry was normal. Peripheral blood smear (PBS) demonstrated numerous Pelger-Huet anomalous neutrophils with characteristic "pince-nez" nuclei, without significant abnormalities in the other cell lines. Due to the benign clinical nature of hereditary PHA, a bone marrow biopsy is almost never required. However, our patient's persistent and worsening neutropenia was unusual for hereditary PHA, so a bone marrow biopsy was performed to rule out MDS and leukemia. Our patient's bone marrow smears showed dysplastic changes to other cell lines including the megakaryocytes and erythroid precursors. Due to our patient's young age and concern that she may have a more serious marrow disorder, genetic testing was pursued. Germline testing in the LBR gene revealed a heterozygous pathogenic mutation, namely, the PR57837.17 variant, confirming the diagnosis of hereditary disease. The bone marrow biopsy performed on our patient illustrates that the presence of dysplasia does not rule out hereditary PHA and further genetic testing should be done in the appropriate clinical scenario. This case was an atypical presentation of hereditary PHA with confounding morphological features that would typically classify the disease as an acquired or pseudo-PHA, hence acting as a Pseudo-Pseudo-Pelger-Huet Anomaly.
Collapse
Affiliation(s)
- Martin Barnes
- Mather Hospital, Northwell Health, Hematology Oncology Fellowship, 75 North Country Rd, Port Jefferson, NY 11777, USA
| | - Victoria Shklar
- Mather Hospital, Northwell Health, Hematology Oncology Fellowship, 75 North Country Rd, Port Jefferson, NY 11777, USA
| | - Dipen Patel
- Mather Hospital, Northwell Health, Hematology Oncology Fellowship, 75 North Country Rd, Port Jefferson, NY 11777, USA
| | - Harry Staszewski
- New York Cancer and Blood Specialists, 49 Nesconset Highway, Port Jefferson Station, NY 11776, USA
| |
Collapse
|
3
|
Horiuchi Y, Hayashi F, Iwasaki Y, Matsuzaki A, Nishibe K, Kaniyu K, Marutani S, Saito K, Matsuoka S, Uchihashi K, Miida T, Ai T, Tabe Y. Peripheral granular lymphocytopenia and dysmorphic leukocytosis as simple prognostic markers in COVID-19. Int J Lab Hematol 2021; 43:1309-1318. [PMID: 34523805 PMCID: PMC8653062 DOI: 10.1111/ijlh.13696] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Revised: 08/11/2021] [Accepted: 08/19/2021] [Indexed: 12/11/2022]
Abstract
Introduction Developing prognostic markers can be useful for clinical decision‐making. Peripheral blood (PB) examination is simple and basic that can be performed in any facility. We aimed to investigate whether PB examination can predict prognosis in coronavirus disease (COVID‐19). Methods Complete blood count (CBC) and PB cell morphology were examined in 38 healthy controls (HCs) and 40 patients with COVID‐19. Patients with COVID‐19, including 26 mild and 14 severe cases, were hospitalized in Juntendo University Hospital (Tokyo, Japan) between April 1 and August 6, 2020. PB examinations were performed using Sysmex XN‐3000 automated hematology analyzer and Sysmex DI‐60 employing the convolutional neural network‐based automatic image‐recognition system. Results Compared with mild cases, severe cases showed a significantly higher incidence of anemia, lymphopenia, and leukocytosis (P < .001). Granular lymphocyte counts were normal or higher in mild cases and persistently decreased in fatal cases. Temporary increase in granular lymphocytes was associated with survival of patients with severe infection. Red cell distribution width was significantly higher in severe cases than in mild cases (P < .001). Neutrophil dysplasia was consistently observed in COVID‐19 cases, but not in HCs. Levels of giant neutrophils and toxic granulation/Döhle bodies were increased in severe cases. Conclusion Basic PB examination can be useful to predict the prognosis of COVID‐19, by detecting SARS‐CoV‐2 infection‐induced multi‐lineage changes in blood cell counts and morphological anomalies. These changes were dynamically correlated with disease severity and may be associated with disruption of hematopoiesis and the immunological system due to bone marrow stress in severe infection.
Collapse
Affiliation(s)
- Yuki Horiuchi
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan
| | | | | | - Akihiko Matsuzaki
- Department of Next Generation Haematology Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan
| | - Kumiko Nishibe
- Department of Next Generation Haematology Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan
| | - Kimiko Kaniyu
- Department of Next Generation Haematology Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan
| | - Setsuko Marutani
- Department of Next Generation Haematology Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan
| | - Kaori Saito
- Department of Next Generation Haematology Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan
| | - Sachiko Matsuoka
- Department of Next Generation Haematology Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan
| | | | - Takashi Miida
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan
| | - Tomohiko Ai
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan
| | - Yoko Tabe
- Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan.,Department of Next Generation Haematology Laboratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-ku, Japan
| |
Collapse
|
5
|
Konishi T, Muto H, Sakuma R, Miyawaki S, Ohashi K, Doki N, Tomiyama J. Familial case of hereditary Pelger-Huët anomaly. Int J Hematol 2019; 110:127-128. [DOI: 10.1007/s12185-019-02677-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Revised: 05/23/2019] [Accepted: 05/28/2019] [Indexed: 11/28/2022]
|